Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC): 5,289 patients (pts) from the ARCAD Clinical Trials Program.
Nadine J. McCleary(Harvard University), Qian Shi(Mayo Clinic), Leonard B. Saltz(Memorial Sloan Kettering Cancer Center), William S. Harmsen(Mayo Clinic), Dirk Arnold(Asklepios Klinik Altona), Aimery de Gramont(Institut Hospitalier Franco Britannique), Miriam Koopman(Utrecht University), Paulo M. Hoff(Translational Research in Oncology), Eric VanCutsem(Peter MacCallum Cancer Centre), Richard M. Goldberg(Ontario Institute for Cancer Research), Bruce J. Giantonio(Northwestern University), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Alberto F. Sobrero(Ospedale Policlinico San Martino), Mace L. Rothenberg(Vanderbilt University), Alfredo Falcone(Azienda Ospedaliero-Universitaria Careggi), Henry C. Pitot(Mayo Clinic), Josep Tabernero(Deaconess Hospital)
Cited by 0
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k